Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients
Joint Authors
Maria, Ala Muhammad
al-Shabini, Muhammad
al-Saqqa, Ayman Muhammad
Zamzam, Yumna
Source
Journal of the Egyptian National Cancer Institute
Issue
Vol. 30, Issue 2 (30 Jun. 2018), pp.49-55, 7 p.
Publisher
Cairo University National Cancer Institute
Publication Date
2018-06-30
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Purpose: The purpose of this work was to assess the truncated form of human epidermal growth factor receptor 2 (HER2) such as p95-HER2 expression in HER2-positive breast cancer (BC) patients who developed metastatic disease after adjuvant treatment with a trastuzumab-containing regimen.
Patients and methods: Thirty-two histologically diagnosed HER2-positive BC patients who developed distant failure after treatment with trastuzumab-based chemotherapy (CT) regimen as an adjuvant therapy were included in the study.
Immunohistochemistry (IHC) method was used to analyze p95-HER2 expression in the formalin-fixed, paraffin-embedded (FFPE) blocks of the enrolled patients.
Results: p95-HER2 was positive in 34.4% of the patients.
The median overall survival (OS) was 22.5 and 35 months for p95-HER2 positive and negative patients, respectively (p = 0.036) and the median time to metastases was 14 and 21 months, respectively (p = 0.006).
There was a statistically significant association between positive p95-HER2 expression and negative hormonal receptors expression (p = 0.004), high Ki-67 expression (p < 0.001) and development of visceral metastasis (p = 0.034).
Conclusion: Expression of p95-HER2 in HER2-positive BC patients is significantly associated with negative hormonal receptors expression, high Ki-67 expression, presence of visceral metastases and worse overall survival.
A larger study is required to confirm its association with different prognostic factors and its effect on survival.
American Psychological Association (APA)
Maria, Ala Muhammad& al-Shabini, Muhammad& al-Saqqa, Ayman Muhammad& Zamzam, Yumna. 2018. Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients. Journal of the Egyptian National Cancer Institute،Vol. 30, no. 2, pp.49-55.
https://search.emarefa.net/detail/BIM-837884
Modern Language Association (MLA)
Maria, Ala Muhammad…[et al.]. Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients. Journal of the Egyptian National Cancer Institute Vol. 30, no. 2 (Jun. 2018), pp.49-55.
https://search.emarefa.net/detail/BIM-837884
American Medical Association (AMA)
Maria, Ala Muhammad& al-Shabini, Muhammad& al-Saqqa, Ayman Muhammad& Zamzam, Yumna. Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients. Journal of the Egyptian National Cancer Institute. 2018. Vol. 30, no. 2, pp.49-55.
https://search.emarefa.net/detail/BIM-837884
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 54-55
Record ID
BIM-837884